Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis

Thomas Gremmel; Cihan Ay; Julia Riedl; Christoph W. Kopp; Beate Eichelberger; Renate Koppensteiner; Simon Panzer

doi:10.1160/th15-07-0598

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2016; 115(03): 615-621
DOI: 10.1160/th15-07-0598

Cellular Haemostasis and Platelets

Schattauer GmbH

Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis

Thomas Gremmel

¹Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

,

Cihan Ay

²Clinical Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

,

Julia Riedl

²Clinical Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

,

Christoph W. Kopp

¹Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

,

Beate Eichelberger

³Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria

,

Renate Koppensteiner

¹Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

,

Simon Panzer

³Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria

› Institutsangaben

Abstract

Summary

Platelet activation and thrombin generation are crucial steps in primary and secondary haemostasis. However, both also play major roles in intravascular thrombus formation and therefore in the development of adverse cardiovascular events. In the current study, we first sought to investigate the associations of the platelet biomarkers platelet factor (PF)-4, thrombospondin (TSP)-1, soluble CD40 ligand (sCD40L), and soluble P-selectin (sP-selectin) with each other and with monocyte-platelet aggregate (MPA) formation in 316 patients undergoing angioplasty and stenting. To better understand the interplay between platelet activation and thrombin generation, we subsequently investigated the associations of the platelet biomarkers with thrombin generation potential. The mostly platelet-specific markers PF-4, TSP-1 and sCD40L correlated strongly with each other (all p < 0.001), and the best correlation was observed between PF-4 and TSP-1 (r=0.91). In contrast, sP-selectin, which derives from platelets and endothelial cells, correlated rather poorly with TSP-1 (r=0.12, p=0.04), and did not correlate with PF-4 and sCD40L. While PF-4, TSP-1 and sP-selectin correlated significantly with in vivo MPA formation (all p < 0.001), no such association was found between sCD40L and MPA formation. PF-4, TSP-1 and sCD40L correlated strongly with peak thrombin generation (all p < 0.001) with the best correlation between PF-4 and peak thrombin generation (r=0.55), whereas sP-selectin did not correlate with peak thrombin generation. Likewise, PF-4, TSP-1 and sCD40L correlated significantly with the area under the thrombin generation curve (AUC; all p< 0.01), whereas sP-selectin did not correlate with the AUC. In conclusion, platelet-specific markers are associated with MPA formation and thrombin generation potential in patients with advanced atherosclerosis.

Keywords

Platelet factor-4 - thrombospondin-1 - soluble CD40 ligand - soluble P-selectin - thrombin generation potential

Volltext

Referenzen

References
1 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
2 Gremmel T, Frelinger AL, Michelson AD. Platelet Physiology. Semin Thromb Haemost. 2015 in print.
3 Ferroni P, Riondino S, Vazzana N. et al. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost 2012; 108: 1109-1123.
4 Kowalska MA, Rauova L, Poncz M. Role of the platelet chaemokine platelet factor 4 (PF4) in haemostasis and thrombosis. Thromb Res 2010; 125: 292-296.
5 Starlinger P, Moll HP, Assinger A. et al. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 2010; 8: 1809-1819.
6 Pusuroglu H, Akgul O, Erturk M. et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis 2014; 25: 558-564.
7 Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ. et al. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res 2007; 121: 293-299.
8 Varo N, de Lemos JA, Libby P. et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-1052.
9 Heeschen C, Dimmeler S, Hamm CW. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
10 Blann AD, Lip GY, Beevers DG. et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-1080.
11 Fijnheer R, Frijns CJ, Korteweg J. et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-1085.
12 Gremmel T, Kopp CW, Seidinger D. et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists‘-inducible platelet reactivity. Atherosclerosis 2009; 207: 608-613.
13 Gremmel T, Koppensteiner R, Kaider A. et al. Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb Haemost 2014; 113: 806-812.
14 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
15 Schrottmaier WC, Kral JB, Badrnya S. et al. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 2015 Epub ahead of print.
16 Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway-- a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
17 Engelmann B. Initiation of coagulation by tissue factor carriers in blood. Blood Cells Mol Dis 2006; 36: 188-190.
18 Morrow DA, Braunwald E, Bonaca MP. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
19 Gremmel T, Eslam RB, Koppensteiner R. et al. Prasugrel reduces agonists’ indu-cible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovas Ther 2013; 31: e40-45.
20 Gremmel T, Panzer S, Steiner S. et al. Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Thromb Res 2013; 132: e24-30.
21 Kiskin NI, Hellen N, Babich V. et al. Protein mobilities and P-selectin storage in Weibel-Palade bodies. J Cell Sci 2010; 123: 2964-2975.
22 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
23 Kyrle PA, Hron G, Eichinger S. et al. Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost 2007; 97: 880-883.
24 Ay C, Jungbauer LV, Kaider A. et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembol-ism. Thromb Haemost 2008; 99: 899-904.
25 Ay C, Jungbauer LV, Sailer T. et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007; 53: 1235-1243.
26 Ay C, Simanek R, Vormittag R. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-2708.
27 Rondina MT, Lappe JM, Carlquist JF. et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 2008; 109: 196-201.
28 Tanne D, Haim M, Goldbourt U. et al. CD40 ligand and risk of ischaemic stroke or coronary events in patients with chronic coronary heart disease. Int J Cardiol 2006; 107: 322-326.
29 Ay C, Dunkler D, Simanek R. et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-2103.
30 Hron G, Kollars M, Binder BR. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
31 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
32 Riedl J, Hell L, Kaider A. et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets. 2015 Epub ahead of print.
33 Azar RR, Kassab R, Zoghbi A. et al. Effects of clopidogrel on soluble CD40 lig-and and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521.e1-521.e4.
34 Gremmel T, Frelinger 3rd AL, Michelson AD. Soluble CD40 ligand in aspirin-treated patients undergoing cardiac catheterization. PLoS One 2015; 10: e0134599
35 Valdes V, Nardi MA, Elbaum L. Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. J Thromb Thrombolysis 2015; 40: 83-87.